Debiopharm International SA and the Paul Scherrer Institute Announce a Licensing Agreement for the Development of a Novel Targeted Radiotherapeutic Product in Oncology
LAUSANNE, Switzerland, Oct. 11, 2018 /PRNewswire/ -- Debiopharm International SA (Debiopharm), a Swiss-based biopharmaceutical company and the Paul Scherrer Institute (PSI), the largest research institute for natural and engineering sciences in Switzerland, today announced a collaboration to pursue the development of a radioconjugated minigastrin analogue (Debio 1124) for cancer patients.
Debio 1124 is a new-generation peptide analogue of minigastrin, coupled to the isotope 177Lutetium. It belongs to the emerging class of Peptide Receptor Radionuclide Therapies and has been designed to selectively radiate tumor cells expressing the Cholecystokinin B Receptor (CCK2R). The compound can also be used as a sensitive diagnostic tool so that an initial imaging step allows the selection of patients who are most likely to benefit from this innovative treatment.
Debio 1124 is currently being developed in advanced Medullary Thyroid Cancer and will be further investigated in other tumor types expressing CCK2R.
"Molecular-targeted radiotherapy has proven to be an efficient way to direct the tumoricidal effects of radiation while minimizing the potential damage of healthy tissues. We look forward to exploring the potential of this innovative product in the clinic and to providing new treatment options to well defined patient groups".
" PSI has once more fulfilled its societal mission with the transfer of Debio 1124 into direction of market maturity and which will hopefully contribute to improve treatment outcome of cancer patients in the future. We are proud that we will proceed with this mission in cooperation with a Swiss based pharmaceutical company such as Debiopharm".
About the Paul Scherrer Institute
About Debiopharm International SA
View original content:http://www.prnewswire.com/news-releases/debiopharm-international-sa-and-the-paul-scherrer-institute-announce-a-licensing-agreement-for-the-development-of-a-novel-targeted-radiotherapeutic-product-in-oncology-300729254.html
SOURCE Debiopharm International SA